Loss of Nrf2 signaling increases susceptibility to acute toxicity, inflammation, and carcinogenesis in mice due to the inability to mount adaptive responses. By contrast, disruption of Keap1 (a cytoplasmic modifier of Nrf2 turnover) protects against these stresses in mice; although inactivating mutations in Keap1 have been identified recently in some human cancers.
Synthetic oleanane triterpenoids have recently been shown to be extremely potent inducers of Nrf2 signaling in vivo [10] . Although originally developed as anti-inflammatory agents, rodent studies have shown that this class of triterpenoids provides chemoprotection against several disease states through induction of Nrf2-regulated genes. For example, CDDOIm is an effective chemopreventive agent against aflatoxin-induced hepatic tumorigenesis, with pronounced protection at oral doses as low as 1 µmol/kg body weight and complete inhibition of tumorigenesis at 100 µmol/kg body weight. Protection is achieved through induction of Nrf2-regulated hepatic detoxification and cytoprotective genes, resulting in reduced aflatoxin-DNA adduct formation and inhibition of tumorigenesis [11] . This class of triterpenoids has also been shown to reduce the number, size, and severity of lung tumors induced by vinyl carbamate [12] .
Furthermore, protection is not limited to carcinogenesis; treatment with triterpenoids protects against cigarette smoke-induced emphysema and cardiac dysfunction through activation of Nrf2 signaling [13] . The broad tissue distribution of these agents combined with potent activation of Nrf2-regulated cytoprotective responses make synthetic oleanane triterpenoids ideal agents for chemoprevention.
Nrf2 signaling can be constitutively activated by deletion of Keap1. Furthermore, tissue specific disruption of Keap1 in mice has been shown to protect against toxic insults such as methylmercury [14] and acetaminophen [15] , as well as acute inflammatory liver injury [16] . In contrast, inactivating mutations in Keap1 have been identified recently in some human cancers, including non small cell lung cancer [17] and breast cancer [18] . Activation of Nrf2 signaling in tumor cells may provide a survival advantage and promote resistance to chemotherapy. Global gene expression changes induced by alteration of Nrf2 signaling have not yet been fully characterized. Global characterization of Nrf2 activation is important to exploit this pathway for chemoprevention in healthy, yet at-risk individuals and also to elucidate the consequences of hijacking the pathway in Keap1-mutant human cancers. Our study addresses this issue by coupling global gene expression analysis of genetic Nrf2 activation in liver-targeted conditional Keap1-null (CKO) mice with analysis of pharmacologic activation using the extremely potent Nrf2 inducer CDDO-Im [10, 11, 19, 20] . CKO mice are an ideal model for genetic activation of Nrf2 signaling, as it is well established that modification of Keap1 function primarily results in changes in Nrf2 activity. For example, Keap1-null mice die just prior to weaning due to hyperkeratosis of the forestomach and esophagus related to Nrf2-regulated changes in several squamous epithelial genes; breeding Keap1-null mice with Nrf2-deficient mice reverses this phenotype [21] . In addition, early studies of RNA transcripts increased in the CKO mouse (compared to wild-type) show that the vast majority of genes modulated were either known Nrf2 targets or contained an ARE in their regulatory region [15] .
The comparisons used in our study provide a unique opportunity to gain insight into pathways modulated by differing modes of Nrf2 activation. In addition, we are able to broadly evaluate the pharmacodynamic action of CDDO-Im in order to identify the predominant molecular pathways contributing to the chemopreventive action of CDDO-Im. The results described in this study can also be used to consider how CDDO-Im or other Nrf2 inducers could best be used for cancer chemoprevention.
Materials and methods

Chemicals
CDDO-Im (1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole) was synthesized as previously described [22] . (genetic control, WT) mice were generated on a C57BL/6J background [15] . While this targeting strategy results in complete disruption of Keap1 in hepatocytes, these animals exhibit hypomorphic expression of Keap1 in other cell types (our unpublished results). Genotypes were assigned using PCR analysis of tail genomic DNA and later confirmed using hepatic genomic DNA. Nrf2-disrupted mice were generated from inbred Nrf2-heterozygous mice on a C57BL/6J background [23] . For gene expression analyses, mice were gavaged with a single dose of 30 µmol CDDO-Im/kg body weight or vehicle consisting of 10% Cremophor-EL (Sigma-Aldrich, St. Louis, MO), 10% dimethyl sulfoxide, and 80% PBS and sacrificed 6 h later. This dose of CDDO-Im is known to be a maximal Nrf2 activating dose [10] that also provides protection against tumorigenesis [11] .
Animals and treatment
Nqo1 transcript measurement
Total RNA was isolated from individual snap frozen livers using Versagene RNA purification kit (Gentra Systems, Minneapolis, MN) and cDNA was synthesized using iSCRIPT cDNA Synthesis Kit (Bio-Rad, Hercules, CA). Gene expression measurements were performed using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA) and iQ Supermix (Bio-Rad). Gene expression measurements were normalized to the endogenous reference gene Gapdh which was not modulated. Fold-change values for gene expression data from real-time quantitative PCR was determined using the 2 -ΔΔCt relative quantification method as published [24] .
Microarray preparation
Total RNA was isolated as above. RNA quality was evaluated using an Agilent Bioanalyzer 2100 (Applied Biosystems). Purified RNA was used for doubled stranded cDNA synthesis. Doubled stranded cDNA synthesis was performed using the Superscript Doubled Stranded cDNA synthesis kit (Invitrogen, Carlsbad, CA). cRNA synthesis was then performed using the Bioarray High Yield RNA Transcript Labeling Kit (Enzo, Farmingdale, NY). Both cDNA and cRNA were purified using the Affymetrix GeneChip Sample Cleanup Module (Affymetrix, Santa Clara, CA ). cRNA was used for the fragmentation reaction. The entire fragmentation product was then hybridized to the Affymetrix Mouse Genome 430 2.0 array chip for 18 hours. The chips were removed, washed and stained using an Affymetrix GeneChip Fluidics Station 400.
The chips were then scanned using an Affymetrix GeneChip Scanner 3000 7G.
Microarray data analysis
The .CEL files were background-corrected using the bg.adjust.gcrma function of gcrma v.2.12.1 [25] , then base 2 logarithm-transformed. The transformed data was quantile-normalized using the normalize.AffyBatch.quantiles function of affy v.1.8.1 [26] as implemented in R v.2.7.0. Each probe set was modeled independently using a linear fixed effects model adapted from [27] to account for fixed treatment, genotype, and probe affinity effects. The linear fixed effects model and filtering procedures are described in detail in the Supplementary Methods. Briefly, Present (P) and Absent (A) calls were used to filter for probe sets that had at least 2 P calls in any 3 replicates of any treatment or genotype groups. A 1.7-fold change threshold was also used. A false discovery rate procedure [28] was applied to correct for multiple hypothesis testing. Each p-value was assigned a corresponding q-value to identify differentially expressed probe sets with high statistical significance at a 5 percent false discovery rate. Several genes were selected from the resulting gene lists for validation by real-time PCR using TaqMan Gene Expression Assays (Applied Biosystems). Microarray data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE15633.
Biological questions and gene lists
Comparisons were designed to address several biological questions, as described below. Sample vials were placed in a Waters 2695 HPLC and held at 5°C prior to loading on a Waters XTerra MS C18 5 µm column protected by a Waters 2.1x10mm Guard Column. Sample (25-100 µl) was loaded, with initial column conditions 46% acetonitrile, 10 mM ammonium acetate pH 7.4. The column was subjected to an 8 minute gradient from 46% to 94% acetonitrile and then washed with 94% acetonitrile for 6 minutes before loading the next sample. CDDO-Im was detected using a Waters ZQ mass spectrometer with an electrospray ionization probe. Analysis and quantitation were carried out using the Waters MassLynx software package. Quantitation was against standard curves generated by adding dilutions of compound to acetonitrile extract from control liver.
Measurement of tissue lipid levels
Liver (100 mg) was homogenized in 1 ml of buffer containing 18 mM Tris, pH 7.5, 300 mM mannitol, 50 mM EGTA, and 0.1 mM phenylmethylsulfonyl fluoride. 500 µl of homogenate was mixed with 4 ml chloroform/methanol (2:1) and incubated overnight at room temperature with occasional shaking. Then, 1 ml of dH2O was added, samples were vortexed and centrifuged at 3000 x g for 5 minutes. The lower lipid phase was removed and dried under nitrogen gas. Lipid pellets were dissolved in a mixture of isopropanol and Triton X-100 (4:1). Triglyceride and cholesterol levels were measured using Vet ACE chemistry system (Alfa Wassermann, West Caldwell, NJ). Free fatty acid levels were determined according to manufacturer's instructions (Roche Diagnostics, Germany). Longer treatment periods were used to evaluate CDDO-Im effects on liver lipid content. Mice were treated with 30 µmol CDDO-Im/kg body weight on Monday, Wednesday, and Friday and sacrificed after 1 week or 3 months of treatment.
Results
Activation of Nrf2 signaling through deletion of Keap1 (genetic activation) and maximal pharmacologic activation using CDDO-Im (structure shown in Figure 1 , inset) results in increased hepatic RNA transcripts of a prototypic Nrf2 target gene NAD(P)H dehydrogenase, quinone 1 (Nqo1). The presence of a functional ARE has been confirmed in the regulatory region of mouse Nqo1 [29] . Earlier studies established that treatment of wild-type mice with a single dose of 30 µmol CDDO-Im/kg body weight produced maximal induction of Nqo1 transcripts in liver [10] . This dose has also been shown to provide protection against aflatoxininduced hepatic tumorigenesis [11] . In the present study, mice were treated with a single dose 
Overlapping gene expression changes result from genetic and pharmacologic Nrf2 activation
Gene changes common to genetic and pharmacologic activation of Nrf2 were evaluated to identify the primary biological functions and pathways associated with these genes. Ingenuity Pathways Analysis clustered these gene changes into several functional groups. The five most significant functional categories, in descending order, were lipid metabolism, molecular transport, carbohydrate metabolism, cell signaling, and xenobiotic metabolism (Table I, along with examples from each category). Identification of known Nrf2-dependent genes and biological functions provides internal validation for this approach [3, 30] .
Xenobiotic metabolism is an exceptionally well-characterized function of Nrf2 signaling.
Genetic and pharmacologic activation of Nrf2 signaling result in up-regulation of known Nrf2 target genes in this group, including glutathione S-transferases, glutathione biosynthesis genes, and Nqo1.
Molecular transport changes have also been previously shown to be regulated by Nrf2 signaling. In this study, molecular transport genes were modulated by Keap1 deletion and CDDO-Im treatment. Both solute carrier (Slc) family members and ATP-binding cassette (Abc) transporters were modulated, with the majority being up-regulated.
Unexpectedly, the largest group of overlapping gene changes was associated with lipid metabolism. Genes in this group are primarily down-regulated and relate to lipid and fatty acid biosynthesis. In addition, sterol regulatory element binding transcription factor 1 (Srebf1) is significantly down-regulated by genetic and pharmacologic activation of Nrf2 signaling and is a key regulator of many fatty acid synthesis genes.
Carbohydrate metabolism is also modulated by genetic and pharmacologic activation of Nrf2 signaling. These gene expression changes are related to several different aspects of carbohydrate metabolism, including glycolysis, the pentose phosphate pathway, regeneration of NAD+ for use in glycolysis and fatty acid oxidation, and glycosaminoglycan biosynthesis. These changes are associated with different functions in carbohydrate metabolism, making the overall effect unclear.
Gene expression changes involved in signal transduction were identified following genetic and pharmacologic activation of Nrf2 signaling. However, these changes do not cluster into any one specific pathway. Jun and Myc oncogene transcripts were modulated. In addition, transcript levels of inhibitor of kappaB kinase gamma were increased. Other examples of signaling-related transcript changes include ubiquitin specific peptidases 2 and 7, as well as dual specificity phosphatase 4.
Further analysis of gene changes common to genetic and pharmacologic activation of Nrf2 signaling identified several cell cycle and DNA damage response genes that have not been previously identified as Nrf2-target genes. For example, cyclin-dependent kinase inhibitor 1A (p21) was increased 3.6-and 2.1-fold by genetic and pharmacologic activation, respectively. In addition, cyclin D1 (-3.1-and -2.5-fold), DNA-damage-inducible transcript 4 (10.4-and 8.0-fold), and growth arrest and DNA-damage-inducible 45 gamma (3.8-and 2.4-fold) were modulated by genetic and pharmacologic activation of Nrf2 signaling. It is important to note that the genes associated with DNA damage are not well characterized and may in fact play a part in oxidative stress response [31] .
Genetic activation of Nrf2 signaling results in unique gene expression changes
Genetic activation of Nrf2 signaling resulted in gene expression changes that did not occur through pharmacologic activation with CDDO-Im. While there are nearly 200 genes uniquely modulated in CKO mice, many of these genes have functions associated with the same biological function categories identified as common to genetic and pharmacologic activation, namely lipid metabolism, molecular transport, xenobiotic metabolism, and carbohydrate metabolism (Table II) . This suggests that although similar biological functions are altered, genetic activation results in an amplified response. Many of these genes can be validated as Nrf2-dependent based on previous literature [3, 30, 32, 33] . It is possible that a few of the Keap1-dependent gene expression changes may be Nrf2-independent. However, identification of concordant changes in biological functions between genetic and pharmacologic manipulation, together with the knowledge that most of the Keap1-dependent gene changes are known to be Nrf2-dependent, suggests that this effect is minimal.
The known Nrf2-regulated functions of xenobiotic metabolism and molecular transport Lipid metabolism genes are the largest group of changes unique to CKO mice. These genes are again primarily associated with down-regulation of lipid metabolism and biosynthesis.
In addition, peroxisome proliferator activated receptors alpha and gamma are modulated in CKO mice (Ppara -2.0-fold, Pparg 2.9-fold).
Carbohydrate metabolism gene expression changes unique to CKO mice could not be assigned to any one specific function. These changes include insulin signaling associated genes-insulin-like growth factor 1 and phosphorylase kinase beta; glucose homeostasis regulator-arginine vasopressin receptor 1A; and UDP-glucose pyrophosphorylase 2, which is involved in conversion of glucose-1P to UDP-glucose.
Biological function changes unique to genetic activation in CKO mice were also identified. Protein synthesis changes were identified due to modulation of eukaryotic translation initiation factors (Eifs). Eif2 alpha kinase 2 was down-regulated (-2.3-fold), while Eif4E binding protein 1 and Eif43 member 3 transcripts were increased 1.9-and 4.1-fold, respectively. Downregulation of complement system genes were identified in CKO mice, including complement component 6, complement component 8 alpha, and complement component 8 beta. These complement components are associated with the membrane attack complex, a protein complex formed by complement components 6, 7, 8, and 9 that function to form a pore in a target cell membrane leading to cell lysis. Gene expression changes associated with down-regulation of interferon signaling were also uniquely modulated in CKO mice, including interferon gamma inducible 47, interferon-induced protein with tetratricopeptide repeats 3, interferon dependent positive acting transcription factor 3 gamma, and signal transducer and activator of transcription 1.
CDDO-Im treatment results in unique gene expression changes
CDDO-Im treatment resulted in unique gene expression changes compared to genetic activation of Nrf2 signaling. Fewer biological functions were identified due to the small number of genes uniquely modulated by pharmacologic activation. Some of these changes were still associated with carbohydrate metabolism, however many genes were involved in cell signaling and regulation of gene expression (Table III) . Carbohydrate metabolism genes were associated with the pentose-phosphate shunt, galactose metabolism, and nucleotide-sugar biosynthesis. It is important to note that induction of Nrf2-regulated genes such as those affecting xenobiotic metabolism is subject to sex differences [35] . For example, greater induction of class Alpha, Mu and Pi GST subunits is observed in the livers of female mice treated with butylated hydroxyanisole than in the livers of male mice treated with the same phenolic antioxidant.
Gender differences have also been observed for the expression of genes affecting lipid at Pennsylvania State University on February 23, 2013 http://carcin.oxfordjournals.org/ Downloaded from metabolism [36] . The comparisons described in our study were all conducted in male mice.
While it is likely that the overall conclusions would remain the same, comparisons using female mice could result in different magnitudes of gene induction. While Nrf2 is commonly described as a mediator of cytoprotective stress responses, our results suggest that the impact of activating this pathway must be considered more broadly. In fact, regulation of lipid metabolism appears to be a primary function of Nrf2 signaling in the mouse liver. Lipid metabolism genes are modulated by genetic activation and pharmacologic activation using CDDO-Im, hinting that Nrf2 signaling may also function to sense lipid levels or intermediates of lipid metabolism. Currently, it is unclear how Nrf2-regulated modulation of lipid metabolism may, if at all, impact the cytoprotective and detoxication changes that are desirable for cancer chemoprevention. However, it raises interesting possibilities for obesity-related cancers and suggests the possibility of targeting Nrf2 signaling for prevention of other disease states associated with lipid metabolism. Our results suggest that Nrf2-inducing agents such as CDDO-Im could be applied to prevent or reverse obesity and diabetes. In fact, recent studies conducted in our lab have shown that CDDO-Im protects against several aspects of high fat diet-induced obesity and diabetes (Shin S., et al. manuscript in review). CDDO-Im prevents increases in total body weight and adipose tissue weight in mice fed a high fat diet in an Nrf2-dependent manner. In addition, CDDO-Im improves glucose tolerance in mice fed a high fat diet. Another known Nrf2 inducer, 3H-1,2-dithiole-3-thione, has also been shown to repress gene expression related to lipid metabolism [3, 37] , suggesting that this effect may be shared by other inducers. Epidemiologic evidence suggests that obesity is a risk factor for cancer incidence and mortality [38] . A large cohort study conducted by the American Cancer Society estimates that 14% of all cancer deaths in men and 20% of all cancer deaths in women from several cancer types are attributable to overweight and obesity [39] . The exact mechanisms responsible for the connection between obesity and carcinogenesis remain unclear; however, at Pennsylvania State University on February 23, 2013 http://carcin.oxfordjournals.org/ Downloaded from obesity-related increases in inflammation may play a role [40] . CDDO-Im and other Nrf2 inducers could protect against both obesity and inflammation to prevent cancer.
Our current study provides unique insight into the pharmacodynamic action of CDDO-Im at low doses relevant to cancer chemoprevention. Our observation of Keap1-Nrf2-dependent and CDDO-Im modulated changes in lipid metabolism may provide additional hints regarding CDDO-Im mechanism of action. The core triterpenoid structure is very similar to cholesterol, perhaps providing a mechanism for increased specificity or potency to activate Nrf2 signaling pathways by mimicking a lipid metabolism intermediate that could be sensed by Keap1. The cholesterol-like structure of this class of synthetic triterpenoids has been implicated in other molecular functions associated with apoptosis. While these latter experiments were conducted at concentrations much higher than is required for Nrf2 activation, the cholesterol-like action is still noteworthy. The analog CDDO-Me has been shown to act in a manner very similar to cholesterol to induce apoptosis by directly permeabilizing the inner mitochondrial membrane [41] . Cholesterol deposition in the mitochondrial membrane alters membrane fluidity and can result in a loss of mitochondrial glutathione. Like cholesterol, CDDO-Me appears to target the inner mitochondrial membrane to induce apoptosis and inhibit mitochondrial electron transport.
While our study shows that Nrf2 signaling is the primary pathway modified by low dose CDDO-Im treatment, molecular pathways modulated by triterpenoids vary depending on the dose. Low concentrations of triterpenoids (in picomolar range) have also been shown to activate an anti-inflammatory response. However, the anti-inflammatory activity of triterpenoids is closely correlated with Nrf2 activation, suggesting a common molecular mechanism [19] .
Additional gene expression changes were identified at the low dose used in our current study.
These changes were not associated with any one predominant pathway, but suggest limited gene expression changes related to apoptosis, NfκB, TGF-β, insulin, and cytokine signaling pathways at this low dose. While Nrf2 activation seems to be predominant and consistent in multiple tissue types and cell lines at low doses [10, 16, 20, 42] ), as described in Methods. ), as described in Methods. Under these constraints, the model parameters have the following interpretations: α represents the average probe intensity; τ 2 is the treatment effect for CDDO-Im treatment in wild-type mice; p π is the probe affinity effect for probe p; σ 2 is the genetic background effect comparing CKO mice to wild-type mice in the vehicle treatment ; is the interaction between treatment t and the genetic background k; is the interaction between the treatment t and the affinity probe p; is the interaction between the affinity probe p and the genetic background k.
To reduce the noise inherent in the GeneChip®, a filtering procedure was applied to the dataset using Present (P) and Absent (A) calls produced by mas5calls function with the default parameters of the affy package version 1.8.1 [2] . Only probe sets that had at least 2 P calls in any 3 replicates of any treatment or genotype groups were kept for further analysis. A 1.7-fold change threshold was also applied to eliminate probe sets with small expression ratios. A false discovery rate procedure [4] was applied to correct for multiple hypothesis testing. Each p-value was assigned a corresponding q-value to identify differentially expressed probe sets with high statistical significance at a 5 percent false discovery rate.
Biological questions and gene lists
The gene lists in this experiment were produced based on the linear model analysis.
Depending on the biological questions, different statistical criteria were applied to generate the answers. First, we sought to identify all genes that are modulated by genetic activation of Nrf2 through deletion of Keap1. This total set of Keap1-Nrf2-dependent genes was determined by selecting probe sets that had the q-value for testing the genotype effect in vehicle treated mice less than 0.05 and the absolute estimate of this effect greater than or equal to 0.77 (the 1.7-fold change threshold in base 2 logarithm). We then defined the genes that are modulated by pharmacologic activation using CDDO-Im. This total set of CDDO-Im modulated genes was determined by selecting probe sets that had the treatment effect in wild-type mice significant and its corresponding absolute estimate met the fold change cutoff. We then identified genes uniquely modulated by genetic activation and not affected by CDDO-Im.
This was accomplished by first determining the complement gene list of genetically modulated genes by setting the q-value of treatment effect in wild-type mice to be greater than or equal to 0.05 or setting the absolute estimate of this treatment effect less than 0.77. Then, we only kept the probe sets that had the genotype effect in vehicle treated mice significant and its absolute estimate of this effect greater than or equal to 0.77. Similarly, genes that are unique to CDDO-Im treatment were also determined.
This set of Keap1-Nrf2-independent genes (CDDO-Im "off-target" genes) was generated first by taking the complement of the pharmacologic activation list by using the genotype effect q-value and its corresponding estimate in vehicle treated mice and applying the same cutoff as above. Then, we selected the probe sets that had treatment effect in wild-type mice with q-values less than 0.05 and the corresponding absolute estimate met the fold change threshold. The CDDO-Im modulated and Keap1-Nrf2-dependent gene lists (common to genetic and pharmacologic activation) were generated by combining the criteria used to identify the separate lists of genes modulated by genetic and pharmacologic activation.
The effect of CDDO-Im treatment in CKO mice was studied to provide secondary confirmation of CDDO-Im modulated, Keap1-Nrf2-independent gene changes. In this analysis, only Keap1-Nrf2-independent genes are expected to be modulated due to the state of constitutive Nrf2 hyperactivation in CKO mice. The gene list was produced by setting the treatment effect in CKO mice q-value less than 0.05 and its corresponding absolute estimate greater than or equal to 0.77. ), as described in Methods.
